Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.

NCT02227433 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT02227433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02227433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Completed
Start date
February 4, 2013
Completion date
April 30, 2020
Enrollment
20 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma